Cashu
Arch Biopartners Inc. Advances Phase II Trial of LSALT Peptide for Kidney Injury Prevention
9 months ago
Stocks
Health Care
arch.v
Arch Biopartners Inc
TSXV: ARCH.V
+0.14 (+13.86%)
1.15
USD
At close at Feb 04, 18:30 UTC
Latest Arch Biopartners Inc News
FinnHub
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
10 months ago
FinnHub
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
10 months ago
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.